CPT1A and head and neck squamous cell carcinoma: Notably, FAT1‐mutant HNSCC cells exhibit resistance to the TCA cycle inhibitor CPI‐613 through activation of CPT1A‐mediated FAO, whereas genetic ablation of mutant FAT1 restores sensitivity to CPI‐613.